Bupivacaine liposome — Competitive Intelligence Brief

Bupivacaine liposome (Bupivacaine liposome) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (liposomal formulation). Area: Anesthesia/Pain Management.

marketed Local anesthetic (liposomal formulation) Voltage-gated sodium channels Anesthesia/Pain Management Small molecule

Target snapshot

Bupivacaine liposome (Bupivacaine liposome) — Tianjin Medical University General Hospital. Bupivacaine liposome is a long-acting local anesthetic that blocks sodium channels in nerve cell membranes, with the liposomal formulation providing sustained drug release for prolonged anesthesia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine liposome TARGET	Bupivacaine liposome	Tianjin Medical University General Hospital	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Articaine hydrochloride 2% solution	Articaine hydrochloride 2% solution	Helsinki University Central Hospital	marketed	Local anesthetic (amide type)	Voltage-gated sodium channels
Levobupivacaine plus sufentanil epidural infusion	Levobupivacaine plus sufentanil epidural infusion	University of Genova	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu-opioid receptor (sufentanil)
Replacement with Zonisamide	Replacement with Zonisamide	Eisai Inc.	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels
Lidocaine + Esmolol (Combo)	Lidocaine + Esmolol (Combo)	Cedars-Sinai Medical Center	marketed	Local anesthetic + Beta-1 selective adrenergic antagonist	Voltage-gated sodium channels (lidocaine); Beta-1 adrenergic receptor (esmolol)
Systemic Dexamethasone plus perineural bupivacaine	Systemic Dexamethasone plus perineural bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Combination therapy: corticosteroid + local anesthetic	Glucocorticoid receptor (dexamethasone); voltage-gated sodium channels (bupivacaine)
Standard dose lamotrigine	Standard dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (liposomal formulation) class)

1. Pacira Pharmaceuticals, Inc · 4 drugs in this class
2. Huazhong University of Science and Technology · 1 drug in this class
3. Maimonides Medical Center · 1 drug in this class
4. The Cleveland Clinic · 1 drug in this class
5. The Cooper Health System · 1 drug in this class
6. The University of Texas Health Science Center, Houston · 1 drug in this class
7. Tianjin Medical University General Hospital · 1 drug in this class
8. University of California, Davis · 1 drug in this class
9. Catherine Vandepitte, M.D. · 1 drug in this class
10. Wake Forest University Health Sciences · 1 drug in this class